Pharvaris Netherlands B.v.

This program provides access to an experimental oral medication called deucrictibant for people with hereditary angioedema (HAE) who have no satisfactory alternative treatments for acute attacks. Eligible participants, aged 12 to 75, take the capsule as needed to manage swelling …

This Phase 3 trial tests an oral drug called deucrictibant in adults with acquired angioedema due to C1 inhibitor deficiency, a rare condition causing sudden, painful swelling attacks. The study has three parts: one to see if a daily extended-release tablet can prevent attacks, a…

This Phase 3 study tests a once-daily pill called deucrictibant to prevent swelling attacks in people aged 12 and older with hereditary angioedema (HAE). The trial will enroll 170 participants and monitor safety and attack rates over a long period. Unlike a cure, patients would n…